jamunjar-logo
whatsapp
cartmembermenu
Search for
"test & packages"
"physiotherapy"
"heart"
"lungs"
"diabetes"
"kidney"
"liver"
"cancer"
"thyroid"
"bones"
"fever"
"vitamin"
"iron"
"HTN"

C1q antibodies test, Serum

Immunity
image

Report in 840Hrs

image

At Home

nofastingrequire

No Fasting Required

Details

Autoantibody test targeting C1q complement protein.

₹9,250₹13,214

30% OFF

C1q Antibodies Test Serum - Comprehensive Medical Information Guide

  • Section 1: Why is it done?
    • Test Purpose: The C1q antibodies test detects circulating autoantibodies directed against the C1q component of the complement system. C1q is the first component of the classical complement pathway, and antibodies against it indicate abnormal immune activation and potential immune complex-mediated disease.
    • Primary Clinical Indications: Detection and diagnosis of anti-C1q antibody-associated vasculitis; evaluation of systemic lupus erythematosus (SLE) with immune complex-mediated disease; assessment of lupus nephritis severity and activity; diagnosis of membranoproliferative glomerulonephritis (MPGN); evaluation of other autoimmune conditions with immune complex deposition
    • Clinical Circumstances for Testing: When SLE is suspected or confirmed, particularly with renal involvement; during evaluation of unexplained glomerulonephritis; when vasculitis is suspected; when monitoring disease activity in lupus nephritis; as part of comprehensive autoimmune screening in patients with clinical features suggestive of connective tissue disease; when assessing prognosis and severity of lupus-related renal disease
  • Section 2: Normal Range
    • Reference Range Values: Negative or <20 mU/mL (or <1.0 AU/mL depending on laboratory methodology); most laboratories report results as negative/positive or provide quantitative values in mU/mL (milliUnits per milliliter) or arbitrary units (AU/mL)
    • Units of Measurement: mU/mL (milliUnits per milliliter), AU/mL (arbitrary units per milliliter), or reported as negative/positive; some laboratories may express results as optical density (OD) units
    • Result Interpretation: Negative (<20 mU/mL) = Normal; absence of C1q antibodies; suggests immune system function without this specific autoimmune marker. Positive (≥20 mU/mL) = Abnormal; presence of anti-C1q antibodies; indicates active autoimmune process, typically associated with SLE or vasculitis. Higher titers generally correlate with greater immune complex burden and disease activity.
    • What Normal vs Abnormal Means: Normal results make certain diagnoses less likely but do not exclude active disease; abnormal results strongly suggest immune complex-mediated disease, particularly lupus-related conditions, and warrant further clinical correlation and investigation
  • Section 3: Interpretation
    • Negative Results (<20 mU/mL): Indicates absence of anti-C1q antibodies; reduces likelihood of immune complex-mediated lupus nephritis; does not exclude SLE diagnosis or other systemic autoimmune conditions; may suggest lower disease activity or different disease mechanisms; in context of negative results, should evaluate other lupus-associated antibodies (anti-dsDNA, anti-nucleosome)
    • Borderline/Weak Positive (20-40 mU/mL): Suggests mild to moderate anti-C1q antibody presence; warrants clinical correlation with symptoms and other laboratory findings; repeat testing may be recommended for confirmation; may indicate early or resolving immune complex disease; requires integration with comprehensive clinical assessment
    • Strongly Positive (>40 mU/mL): Indicates significant anti-C1q antibody levels; strongly associated with active immune complex disease; highly predictive of lupus nephritis or vasculitis; suggests substantial complement activation and immune complex deposition; correlates with increased disease severity and renal involvement; indicates need for aggressive monitoring and treatment optimization
    • Factors Affecting Results: Active disease state (higher titers during flares); immunosuppressive therapy (may reduce titers); complement activation status; presence of immune complexes; concurrent infections may transiently elevate levels; laboratory methodology and standardization differences; sample handling and storage conditions; timing of collection relative to disease activity
    • Clinical Significance: Anti-C1q antibodies are highly specific markers of immune complex disease; strong correlation with lupus nephritis and proliferative glomerulonephritis; presence associated with worse renal prognosis; useful predictor of disease flares and renal exacerbations; levels correlate with disease activity; serial measurements help monitor treatment response; persistently positive antibodies indicate ongoing immune complex formation; can appear before clinical disease manifestations; considered marker of severe lupus phenotype
  • Section 4: Associated Organs
    • Primary Organ Systems Involved: Kidneys (primary target organ - glomerulonephritis, lupus nephritis); blood vessels (vasculitis, endothelial injury); immune system (dysregulation, complement activation); skin (cutaneous manifestations, immune complex deposition); joints (arthritis, synovitis); nervous system (CNS involvement); complement system (activation cascade)
    • Diseases Associated with Abnormal Results: Systemic lupus erythematosus (SLE) - particularly with renal involvement; lupus nephritis (proliferative and membranoproliferative forms); ANCA-negative vasculitis; membranoproliferative glomerulonephritis (MPGN); post-infectious glomerulonephritis; cryoglobulinemia; anti-C1q disease (primary); other connective tissue diseases with immune complex pathology; secondary glomerulonephritis
    • Conditions Requiring Further Investigation: Unexplained glomerulonephritis; proteinuria with systemic symptoms; hematuria with autoimmune features; declining renal function of unclear etiology; SLE with renal manifestations; recurrent renal flares; suspected vasculitis; immune complex-mediated disease
    • Potential Complications from Abnormal Results: Progressive renal insufficiency and chronic kidney disease; acute kidney injury with severe immune complex deposition; end-stage renal disease requiring dialysis or transplantation; hypertension secondary to renal disease; cardiovascular complications from systemic inflammation; vasculitis leading to organ ischemia; thrombotic events from endothelial injury; infection risk from required immunosuppressive therapy; neurological manifestations from CNS involvement; cutaneous complications and scarring
    • Prognostic Significance: Presence of anti-C1q antibodies associated with worse renal prognosis in lupus; indicates higher risk of progression to ESRD; correlates with severe proliferative lupus nephritis; predicts increased need for intensive immunosuppression; associated with higher rates of renal flares; elevated levels suggest need for aggressive preventive management
  • Section 5: Follow-up Tests
    • Complementary Autoimmune Tests: Anti-double stranded DNA (anti-dsDNA) antibodies - assess SLE activity and nephritis risk; Anti-nucleosome antibodies - evaluate immune complex disease; Anti-histone antibodies - support SLE diagnosis; Antinuclear antibody (ANA) panel - comprehensive autoimmune screening; Anti-Smith (anti-Sm) antibodies - SLE-specific marker
    • Complement System Evaluation: Serum complement C3 levels - assess complement consumption; Serum complement C4 levels - evaluate classical pathway activation; Total hemolytic complement (CH50) - comprehensive complement function assessment; C1q level - assess C1q component availability; Circulating immune complexes - direct measurement of immune complex burden
    • Renal Function and Proteinuria Assessment: Serum creatinine - assess glomerular filtration rate; Blood urea nitrogen (BUN) - evaluate renal function; Urinalysis with microscopy - detect hematuria and cellular casts; 24-hour urine protein - quantify proteinuria; Urine sediment analysis - assess active urinary findings; Estimated GFR (eGFR) - calculate kidney function
    • Tissue Diagnosis and Imaging: Kidney biopsy with immunofluorescence - definitive assessment of lupus nephritis class; Light microscopy - determine histologic pattern and severity; Electron microscopy - evaluate immune complex ultrastructure; Renal ultrasound - assess kidney size and echogenicity; Renal MRI - detailed anatomic evaluation when indicated
    • Inflammatory Markers: Erythrocyte sedimentation rate (ESR) - assess inflammation; C-reactive protein (CRP) - evaluate acute phase response; Anti-C3b nephritic factor - assess alternative pathway activation; Procalcitonin - differentiate from infection
    • ANCA and Vasculitis Panel: Cytoplasmic ANCA (cANCA)/PR3 - assess for ANCA-associated vasculitis; Perinuclear ANCA (pANCA)/MPO - evaluate ANCA-negative vasculitis patterns; Anti-glomerular basement membrane (GBM) antibodies - exclude Goodpasture syndrome
    • Monitoring Frequency and Serial Testing: For newly diagnosed SLE with positive C1q antibodies: baseline assessment then monitor every 3-6 months; during treatment initiation: monthly monitoring to assess response; for stable disease: every 6-12 months; with clinical flare: immediately repeat C1q antibodies with comprehensive panel; post-treatment: serial measurements to assess durability of response; when considering treatment intensification: obtain current C1q titers
    • Related Tests Providing Complementary Information: Anti-nucleosome antibodies - correlate with C1q for disease activity assessment; Anti-C3 nephritic factor - assess membranoproliferative pathology; Immunoglobulin levels (IgG, IgM) - evaluate humoral immunity; Rheumatoid factor - assess for immune complex disease; Cryoglobulin levels - if vasculitis suspected
  • Section 6: Fasting Required?
    • Fasting Requirement: NO - Fasting is not required for C1q antibodies testing.
    • Patient Preparation Requirements: No special dietary restrictions; patients may eat and drink normally before blood collection; hydration is encouraged to facilitate venipuncture; no required period of fasting prior to testing; testing may be done at any time of day
    • Medications and Preparation: Continue taking all regularly prescribed medications unless specifically instructed otherwise; immunosuppressive drugs (corticosteroids, cyclophosphamide, mycophenolate) do not require interruption; medications do not need to be timed relative to blood draw; inform laboratory of current medications as they may affect interpretation; no need to avoid aspirin or anticoagulants for this specific test (but follow general guidelines for other tests if concurrent)
    • Sample Collection and Handling: Blood sample collected via venipuncture into serum separator tube (SST) or plain gold-top tube; typically 5-10 mL of blood required; sample should be allowed to clot at room temperature; serum separated by centrifugation; sample must be processed and frozen within 2 hours of collection for optimal stability; store at -20°C or -80°C until testing; freeze-thaw cycles should be minimized
    • Important Collection Considerations: Timing of collection may affect results - ideally draw during consistent time of day for serial comparisons; avoid hemolyzed samples as hemolysis may interfere with testing; do not use samples with visible clots; label all samples clearly with patient identifiers; provide clinical history and indication for testing to laboratory; note any concurrent infections or acute illness; document current medications and treatment status on requisition form; for monitoring purposes, use same laboratory when possible for result comparability
    • Post-Collection Considerations: No restrictions on activities after blood draw; patient may resume normal diet and activities immediately; no special post-collection care required; results typically available within 5-7 working days depending on laboratory; expedited testing may be available if clinically indicated; communicate with laboratory if urgent results needed

How our test process works!

customers
customers